COSTA MESA, Calif., July 16, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern Californian announced today the successful completion of a large phase I clinical trial. The study protocol required that WCCT Global enroll 180 patients that would stay in their phase I Clinical Pharmacology Unit for an extended period of time. WCCT Global was able to randomize and accommodate all the needed patient cohorts without delays. WCCTG attributes this success in large part to their patient recruitment process and in-house call center. The full service CRO has performed over 700 clinical trials and more than 30 % of them being specifically phase I clinical trials. In addition to their recruitment process, another contributing factor to the successful patient enrollment is the location of their phase I CPUs. Cypress and Costa Mesa, California is located strategically between Los Angeles and Orange County California with a densely populated area of people eager to participate in clinical trials. Over the years, WCCT Global has built a large database of engaged volunteers which allows their studies to be quickly recruited and enrolled. Their patient database for phase I is comprised of diverse ethnicities including Japanese, Chinese, Spanish, and Caucasian among others.
Jon Rojas, WCCT Global's COO stated, "We are pleased to be one of the leading Contract Research Organizations engaged in the conduct of clinical research and we continue to raise the standards for successful delivery for our sponsors by completing studies such as these without meaningful delays. Our staff, equipment, and expertise are exemplified by our clients continually coming back."
WCCT Global has the tools to run these trials including: atomic clocks and watches for time synchronization, six (6) refrigerated centrifuges, 12+ ECG Machines, three -70º C freezers, several -20º C freezers, several 2-8ºC refrigerators, treadmill equipment, slit lamps, Goldmann and Perkins applanation tonometers, pupillometers, telemetry and holter-capable, stadiometers, crash carts, nitric oxide machine, a platelet aggregometry lab and multiple spirometry units. With this equipment, WCCT Global has the ability to perform large specialized first in human trials requiring specific procedures. With the quick enrollment of the 180 patients, the full service CRO is continually striving for excellence in this very demanding area of clinical reasearch.
More about WCCT Global:
WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
If you are interested in visiting one of our Clinical Pharmacology Units, Click Here and request a time visit.
Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global